Effects of physical exercise on cancer-related cognitive impairment Protocol for an umbrella review
Article Sidebar
Main Article Content
Abstract
Cancer-related cognitive impairment (CRCI) is a mild but meaningful decline in cognitive function among cancer patients, affecting domains such as memory, attention, and executive functions. Emerging evidence suggests that physical exercise is a promising non-pharmacological strategy to mitigate these symptoms. Although several systematic reviews and meta-analyses have examined this topic, no umbrella review has yet synthesized the full body of evidence. This umbrella review aims to integrate findings on the effects of exercise on different cognitive domains in cancer populations, considering both self-reported and objective outcomes. The review will follow PRIOR guidelines and apply a PRISMA-based search strategy across four databases (MEDLINE/PubMed, Scopus, Web of Science, and SPORTDiscus). Eligibility criteria will follow the PICOS framework, including systematic reviews with or without meta-analyses evaluating exercise interventions and their impact on cognitive outcomes in individuals with cancer. Data on intervention characteristics, cognitive domains, and effect sizes will be extracted, and methodological quality will be assessed using GRADE and AMSTAR-2. This review will offer a comprehensive synthesis of current evidence on exercise and CRCI, helping identify the most responsive cognitive domains, effective exercise modalities, and key methodological gaps to inform future research and evidence-based recommendations for cancer survivors’ cognitive health.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Andrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., Nasser, M., Meerpohl, J., Post, P. N., Kunz, R., Brozek, J., Vist, G., Rind, D., Akl, E. A., & Schünemann, H. J. (2013). GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J. Clin. Epidemiol. 66(7), 719-725. https://doi.org/10.1016/j.jclinepi.2012.03.013
Bai, L., & Yu, E. (2021). A narrative review of risk factors and interventions for cancer-related cognitive impairment. Ann. Transl. Med., 9(1), 72. https://doi.org/10.21037/atm-20-6443
Campbell, K. L., Zadravec, K., Bland, K. A., Chesley, E., Wolf, F., & Janelsins, M. C. (2020). The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: systematic review of randomized controlled trials. Phys. Ther., 100(3), 523-542. https://doi.org/10.1093/ptj/pzz090
Demos-Davies, K., Lawrence, J., & Seelig, D. (2024). Cancer related cognitive impairment: a downside of cancer treatment. Front. Oncol., 14, 1387251. https://doi.org/10.3389/fonc.2024.1387251
Gates, M., Gates, A., Pieper, D., Fernandes, R. M., Tricco, A. C., Moher, D., Brennan, S. E., Li, T., Pollock, M., Lunny, C., Sepúlveda, D., McKenzie, J. E., Scott, S. D., Robinson, K. A., Matthias, K., Bougioukas, K. I., Fusar-Poli, P., Whiting, P., Moss, S. J., & Hartling, L. (2022). Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ, 378, e070849. https://doi.org/10.1136/bmj-2022-070849
Hamilton, S., Oxlad, M., & Sianis, Y. (2024). Experiences of women with breast cancer disclosing cancer-related cognitive impairment symptoms to health professionals: a Systematic review and meta-synthesis. J. Psychosoc. Oncol., 42(6), 888-908. https://doi.org/10.1080/07347332.2024.2342836
Janelsins, M. C., Kesler, S. R., Ahles, T. A., & Morrow, G. R. (2014). Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int. Rev. Psychiatry, 26(1), 102-113. https://doi.org/10.3109/09540261.2013.864260
Kim, H. G., Rashid, M. A., Poleschuk, M., Ullah, F., Lee, S. H., Kim, S. H., Qin, B., Zheng, X. F. S., & Jang, M. H. (2025). Cognitive dysfunction in chemobrain: Molecular mechanisms and therapeutic implications. Biomed. Pharmacother., 192, 118581. https://doi.org/10.1016/j.biopha.2025.118581
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med., 6(7), e1000100. https://doi.org/10.1371/journal.pmed.1000100
Lomeli, N., Lepe, J., Gupta, K., & Bota, D. A. (2021). Cognitive complications of cancer and cancer-related treatments - Novel paradigms. Neurosci. Lett., 749, 135720. https://doi.org/10.1016/j.neulet.2021.135720
Lv, L., Mao, S., Dong, H., Hu, P., & Dong, R. (2020). Pathogenesis, assessments, and management of chemotherapy-related cognitive impairment (CRCI): an updated literature review. J. Oncol., 2020, 3942439. https://doi.org/10.1155/2020/3942439
Mackenzie, L., & Marshall, K. (2022). Effective non-pharmacological interventions for cancer related cognitive impairment in adults (excluding central nervous system or head and neck cancer): systematic review and meta-analysis. Eur. J. Phys. Rehabil. Med., 58(2), 258-270. https://doi.org/10.23736/S1973-9087.21.06898-2
Moruno-Manchon, J. F., Uzor, N. E., Kesler, S. R., Wefel, J. S., Townley, D. M., Nagaraja, A. S., Pradeep, S., Mangala, L. S., Sood, A. K., & Tsvetkov, A. S. (2018). Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol. Cell. Neurosci., 86, 65-71. https://doi.org/10.1016/j.mcn.2017.11.014
Oldacres, L., Hegarty, J., O'Regan, P., Murphy-Coakley, N. M., & Saab, M. M. (2023). Interventions promoting cognitive function in patients experiencing cancer related cognitive impairment: A systematic review. Psycho-Oncol., 32(2), 214-228. https://doi.org/10.1002/pon.6073
Oliva, G., Giustiniani, A., Danesin, L., Burgio, F., Arcara, G., & Conte, P. (2024). Cognitive impairment following breast cancer treatments: an umbrella review. The Oncologist, 29(7), e848-e863. https://doi.org/10.1093/oncolo/oyae090
Olson, B., & Marks, D. L. (2019). Pretreatment cancer-related cognitive impairment-Mechanisms and outlook. Cancers, 11(5), 687. https://doi.org/10.3390/cancers11050687
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., McGuinness, L. A., … Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Ren, X., Boriero, D., Chaiswing, L., Bondada, S., St Clair, D. K., & Butterfield, D. A. (2019). Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment ("chemobrain"), a condition that significantly impairs the quality of life of many cancer survivors. Biochim. Biophys. Acta., 1865(6), 1088-1097. https://doi.org/10.1016/j.bbadis.2019.02.007
Rick, O., Gerhardt, A., & Schilling, G. (2024). Cancer-related cognitive dysfunction: A narrative review for clinical practice. Oncol. Res. Treat., 47(5), 218-223. https://doi.org/10.1159/000538277
Sekeres, M. J., Bradley-Garcia, M., Martinez-Canabal, A., & Winocur, G. (2021). Chemotherapy-induced cognitive impairment and hippocampal neurogenesis: A review of physiological mechanisms and interventions. Int. J. Mol. Sci., 22(23), 12697. https://doi.org/10.3390/ijms222312697
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., & Henry, D. A. (2017). AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 358, j4008. https://doi.org/10.1136/bmj.j4008
Spinetti, D., & Orzelleca, M. (2025). Mapping self-awareness of cancer-related cognitive impairment: a scoping review of evidence, methods, and neurobiological correlates. Front. Neurol., 16, 1662935. https://doi.org/10.3389/fneur.2025.1662935
Wang, X. M., Walitt, B., Saligan, L., Tiwari, A. F., Cheung, C. W., & Zhang, Z. J. (2015). Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine, 72(1), 86-96. https://doi.org/10.1016/j.cyto.2014.12.006
Whittaker, A. L., George, R. P., & O'Malley, L. (2022). Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta-analysis. Sci. Rep., 12(1), 2135. https://doi.org/10.1038/s41598-022-05682-1
Williams, A. M., Zent, C. S., & Janelsins, M. C. (2016). What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br. J. Haematol., 174(6), 835-846. https://doi.org/10.1111/bjh.14211
Yap, N. Y., Toh, Y. L., Tan, C. J., Acharya, M. M., & Chan, A. (2021). Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment. Cytokine, 144, 155556. https://doi.org/10.1016/j.cyto.2021.155556
Zimmer, P., Baumann, F. T., Oberste, M., Wright, P., Garthe, A., Schenk, A., Elter, T., Galvao, D. A., Bloch, W., Hübner, S. T., & Wolf, F. (2016). Effects of exercise interventions and physical activity behavior on cancer related cognitive impairments: a systematic review. BioMed Res. Int., 2016, 1820954. https://doi.org/10.1155/2016/1820954